Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain. Bio- and histochemical evidence suggests a pivotal role of central and peripheral inflammation in its aetiopathology, linked to the production of free radicals. Numerous epidemiological studies support that the long-term use of non-steroidal antiinflammatory drugs is preventive against AD, but these medications do not slow down the progression of the disease in already diagnosed patients. There are a number of studies focusing on traditional herbal medicines and small molecules (usually plant secondary metabolites) as potential anti-inflammatory drugs, particulary in respect to cytokine suppression. For instance, ω-3 polyunsaturated fatty acids and a number of polyphenolic phytochemicals have been shown to be effective against inflammation in animal and cell models. Some of these plant secondary metabolites have also been shown to possess antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects. This review will provide an overview the effects of catechins/proanthocyanidins from green tea, curcumin from turmeric, extracts enriched in bacosides from Brahmi (Bacopa monnieri), flavone glycosides from Ginkgo biloba, and ω-3 polyunsaturated fatty acids. They do not only counteract one pathophysiological aspect of AD in numerous in vitro and in vivo studies of models of AD, but also ameliorate several of the above mentioned pathologies. The evidence suggests that increased consumption of these compounds might lead to a safe strategy to delay the onset of AD. The continuing investigation of the potential of these substances is necessary as they are promising to yield a possible remedy for this pervasive disease.
Keywords: Alzheimer's disease, inflammation, non-steroidal anti-inflammatory drugs, plant secondary metabolites, reactive oxygen species, treatment.
CNS & Neurological Disorders - Drug Targets
Title:Natural Compounds and Plant Extracts as Therapeutics Against Chronic Inflammation in Alzheimer's Disease - A Translational Perspective
Volume: 13 Issue: 7
Author(s): Nadine Apetz, Gerald Munch, Suresh Govindaraghavan and Erika Gyengesi
Affiliation:
Keywords: Alzheimer's disease, inflammation, non-steroidal anti-inflammatory drugs, plant secondary metabolites, reactive oxygen species, treatment.
Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain. Bio- and histochemical evidence suggests a pivotal role of central and peripheral inflammation in its aetiopathology, linked to the production of free radicals. Numerous epidemiological studies support that the long-term use of non-steroidal antiinflammatory drugs is preventive against AD, but these medications do not slow down the progression of the disease in already diagnosed patients. There are a number of studies focusing on traditional herbal medicines and small molecules (usually plant secondary metabolites) as potential anti-inflammatory drugs, particulary in respect to cytokine suppression. For instance, ω-3 polyunsaturated fatty acids and a number of polyphenolic phytochemicals have been shown to be effective against inflammation in animal and cell models. Some of these plant secondary metabolites have also been shown to possess antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects. This review will provide an overview the effects of catechins/proanthocyanidins from green tea, curcumin from turmeric, extracts enriched in bacosides from Brahmi (Bacopa monnieri), flavone glycosides from Ginkgo biloba, and ω-3 polyunsaturated fatty acids. They do not only counteract one pathophysiological aspect of AD in numerous in vitro and in vivo studies of models of AD, but also ameliorate several of the above mentioned pathologies. The evidence suggests that increased consumption of these compounds might lead to a safe strategy to delay the onset of AD. The continuing investigation of the potential of these substances is necessary as they are promising to yield a possible remedy for this pervasive disease.
Export Options
About this article
Cite this article as:
Apetz Nadine, Munch Gerald, Govindaraghavan Suresh and Gyengesi Erika, Natural Compounds and Plant Extracts as Therapeutics Against Chronic Inflammation in Alzheimer's Disease - A Translational Perspective, CNS & Neurological Disorders - Drug Targets 2014; 13 (7) . https://dx.doi.org/10.2174/1871527313666140917110635
DOI https://dx.doi.org/10.2174/1871527313666140917110635 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Evaluation of 3,4,5,4'-trans-tetramethoxystilbene (DMU-212) and Its Analogs Against an Extensive Panel of Human Tumor Cell Lines
Letters in Drug Design & Discovery Central Administration of Neuropeptide FF and Related Peptides Attenuate Systemic Morphine Analgesia in Mice
Protein & Peptide Letters Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Extranuclear Localization of SIRT1 and PGC-1α: An Insight into Possible Roles in Diseases Associated with Mitochondrial Dysfunction
Current Molecular Medicine Pathophysiological Roles of Transglutaminase - Catalyzed Reactions in the Pathogenesis of Human Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry Activin and TGF-β Effects on Brain Development and Neural Stem Cells
CNS & Neurological Disorders - Drug Targets From Antioxidant Chelators to Site-Activated Multi-Target Chelators Targeting Hypoxia Inducing Factor, Beta-Amyloid, Acetylcholinesterase and Monoamine Oxidase A/B
Mini-Reviews in Medicinal Chemistry Combinatory Approaches Targeting Cognitive Impairments and Memory Enhancement: A Review
Current Drug Targets Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors
Current Topics in Medicinal Chemistry Computational Elucidation of Phylogenetic, Functional and Structural Features of Methioninase from <i>Pseudomonas, Escherichia, Clostridium</i> and <i>Citrobacter Strains</i>
Recent Patents on Biotechnology Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued) Epigenetic Regulation of EMT: The Snail Story
Current Pharmaceutical Design Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present)
Current Medicinal Chemistry Cilostazol: Therapeutic Potential Against Focal Cerebral Ischemic Damage
Current Pharmaceutical Design H2O2 Signalling Pathway: A Possible Bridge between Insulin Receptor and Mitochondria
Current Neuropharmacology